Sino Biological is an international reagent supplier and service provider specialising in recombinant protein production and antibody development. All of the company’s products are independently manufactured and produced, and consist of recombinant proteins, antibodies and cDNA.
Sino Biological is a preferred choice when it comes to researchers’ search for technical services for the advanced technology platforms needed. The company also provides pre-clinical production technology services for monoclonal antibody drug candidates.
Sino Biological Inc. (‘Sino Bio’) is a leading global supplier of biological research reagents and related contract research services. The company is headquartered in Beijing, China, and has established subsidiaries in the US, Germany, Japan and South Korea.
Sino Bio became a public company in August 2021, when it successfully completed an IPO on the stock exchange ChiNext, a subsidiary of the Shenzhen Stock Exchange (Sino Biological, 301047).
Comprehensive reagent solutions and CRO services
The company holds an extensive portfolio of about 9,000 recombinant proteins, 14,000 antibodies, 49,000 genes, and multiple serum-free mammalian cell culture media products. These are utilised by over 9,000 customers from pharmaceutical and biotechnology companies as well as research institutions in over 90 countries around the world.
Sino Bio’s proprietary technology platforms also facilitate end-to-end products and services for customers with complex protein and antibody requirements.
Quality and innovation in protein and antibody product development
Led by a group of experienced scientists, the company is constantly growing and focuses on quality and innovation. Sino Bio’s team is continuously growing and currently has more than 1000 members, a third of whom hold Master’s or doctoral-level degrees.
During the last few years, the company has expanded to over 355,000ft², including 215,000ft² of research and development (R&D) and production facilities and over 53,000ft² of GMP-level manufacturing workshops and laboratories, where over 2,000 new protein and antibody products are developed every year.
Many of these new products are best-in-class on the market, including GMP-grade cytokines, enzymes and kinases, as well as full-length multi-transmembrane proteins. The company has also achieved ISO9001, ISO13485, CNAS, CMA, and GMP compliance certification.
About Sino Biological
Sino Bio has long been recognised for its contribution to the field of infectious disease research. The company’s ProvirTM reagent collection is the world’s top viral antigen bank, with thousands of antigens and antibodies for several viral types, including influenza, RSV, and coronavirus strains.
Many of these reagents have been used in manufacturing rapid antigen and antibody diagnostic tests globally. Moreover, the company has won CiteAb’s ‘Supplier Succeeding in SARS-CoV-2 Research’ and ‘Protein Supplier to Watch’ awards for two consecutive years.
Sino Bio aims to advance life science and improve human health through the provision of superior quality research reagents and CRO services. The company will continue to develop new products to address the unmet needs and demands from today’s biomedical research community.
